Oxford Biomedica to expand with fourth site, creating 100 jobs
pharmafile | September 13, 2018 | News story | | Oxford BioMedica, pharma
Gene and cell therapy group Oxford Biomedica has announced plans to expand its business with a new site located not far from its headquarters based in its namesake city of Oxford, UK.
The new location with be the fourth opened by the company, measuring approximately 84,000 square feet; phase one and two of the firm’s expansion plans with occupy around 45,000 square feet for four GMP clean room suites and two fill and finish suites, alongside laboratories, offices and warehouses.
Oxford Biomedica has stated that it plans to open the offices and warehouse in the first quarter of next year, with the additional clean room suites to follow a year later in the first quarter of 2020. Once the facility is fully operational, it would “more than double” the company’s bioprocessing capacity, the firm said, enabling it to rise to meet expected long-term demand and exploit immediate market opportunity. Around 100 new skilled positions are expected to emerge as a result of the expansion.
“We are delighted to secure this new facility in Oxford for our capacity expansion programme,” said John Dawson, Chief Executive Officer at the company. “Oxford BioMedica is a leading gene and cell therapy Group and, following the approval of the first gene therapy in the US, we have seen a step change in business development enquiries for our expertise across the LentiVector enabled platform. With the finances secured earlier this year, we are now able to accelerate our investment in the new facility which, once on stream, will have the capacity to meet the expected long-term demand for lentiviral vectors.”
Matt Fellows
Related Content
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
Johnson & Johnson announces successful results from trial for myeloma treatment
Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed …
Bend Bioscience adds commercial spray drying facility to Georgia site
Bend Bioscience has announced the addition of a commercial-scale spray dryer and a Gerteis dry …
